Kymera Therapeutics Chief Medical Officer Terence Rooney Receives Equity Awards

Executive Compensation Structure at Kymera Therapeutics

The equity awards granted to Terence Rooney on July 27, 2026, consist of two primary components: restricted stock units and stock options. These instruments represent typical elements of compensation packages for senior executives at biopharmaceutical companies. The restricted stock units granted to Rooney total 38,000 shares, while the stock options cover an additional 76,000 shares of common stock. Together, these awards underscore management's direct financial participation in the company's long-term performance and shareholder value creation.

The structure of these equity grants incorporates vesting schedules designed to encourage sustained executive tenure and alignment with shareholder interests. The RSUs and options are contingent upon Rooney's continued employment with Kymera Therapeutics through each respective vesting date. This approach reflects industry-standard practices wherein executives gain economic benefit only if they remain with the company and the underlying equity appreciates in value, thereby tying compensation directly to sustained leadership and corporate performance.

Restricted Stock Units and Vesting Timeline

The restricted stock unit grant to Chief Medical Officer Rooney comprises 38,000 units, with each unit representing a contingent right to receive one share of Kymera Therapeutics' common stock upon vesting and settlement. According to the disclosure, these RSUs are scheduled to vest in four equal annual installments following the grant date of July 27, 2026. This means that Rooney will receive approximately 9,500 shares annually, assuming he remains employed throughout the vesting period and all conditions are satisfied.

The four-year vesting schedule for RSUs is a common mechanism in biotechnology executive compensation, as it encourages long-term commitment to the company's strategic objectives. The filing indicates that vesting is entirely contingent on the reporting person's continued employment through each vesting date. This arrangement protects shareholder interests by ensuring that departing executives do not automatically receive the full benefit of their equity awards, thereby reducing incentives for premature departure and ensuring that management remains focused on achieving milestones essential to the company's success.

Stock Options and Exercise Terms

In addition to the restricted stock units, Rooney was granted 76,000 stock options on July 27, 2026, with an exercise price of $110.05 per share. These options have a ten-year expiration date, extending to July 26, 2036, providing a lengthy window within which Rooney may exercise his right to purchase common stock. The grant price of $110.05 represents the reference value at which Rooney can acquire shares, and the options only become economically valuable if the company's stock price appreciates above this strike price during the option term.

The vesting schedule for these stock options follows a two-phase structure: 25 percent of the underlying shares will vest on July 27, 2027, one year following the grant date, with the remainder vesting in thirty-six equal monthly installments thereafter. This means that after the initial one-year cliff, approximately 19,000 shares become exercisable, followed by monthly vesting of roughly 1,583 shares per month over the subsequent three years. Like the RSU grants, option vesting is contingent upon Rooney's continued employment with Kymera Therapeutics, further reinforcing alignment between executive compensation and long-term company performance.

Direct Ownership and Beneficial Interest

Following the reported transaction on July 27, 2026, the filing indicates that Rooney beneficially owns 38,000 shares through direct ownership in the form of restricted stock units, and holds options covering an additional 76,000 shares. The restricted stock units are recorded as direct beneficial ownership under the common stock category, as each unit carries the contingent right to become a fully vested share upon satisfaction of employment and time-based conditions. The stock options are similarly recorded as direct beneficial ownership, reflecting Rooney's current legal right to exercise those options, even though the underlying shares are not yet owned.

The nature of these holdings represents Rooney's tangible stake in Kymera Therapeutics' future performance. As a senior executive responsible for medical strategy and clinical development decisions, Rooney's personal financial interest in the company's success aligns his decision-making authority with shareholder interests. The filing documents these beneficial ownership positions as of the transaction date, providing transparency regarding management's holdings and potential incentive structures that may influence strategic or operational decisions.

Role and Responsibilities of the Reporting Person

Terence Rooney holds the title of Chief Medical Officer at Kymera Therapeutics, a position critical to the company's clinical development and regulatory strategy. As CMO, Rooney typically bears responsibility for overseeing the medical aspects of the company's drug development programs, including clinical trial design, regulatory submissions, and medical safety assessments. His position places him among the company's senior management team and makes him a Section 16 reporting person under securities law, requiring disclosure of beneficial ownership changes.

The CMO role in biopharmaceutical companies carries substantial influence over research and development priorities, clinical trial outcomes, and interactions with regulatory agencies such as the FDA. Rooney's personal equity stake in Kymera Therapeutics, as documented in this disclosure, creates direct financial incentives aligned with advancing the company's therapeutic programs and achieving positive clinical outcomes. This alignment is particularly significant given the high-risk, high-reward nature of drug development and the substantial regulatory and scientific uncertainties inherent in bringing new therapeutics to market.

Transaction Details and Regulatory Filing

The transaction reported in this disclosure occurred on July 27, 2026, and was filed with the Securities and Exchange Commission under Section 16(a) of the Securities Exchange Act of 1934. The filing identifies Rooney as the sole reporting person, with no joint or group filing indicated. The transaction codes used in the disclosure indicate that the restricted stock units and stock options were acquired (rather than disposed of) by Rooney on the reported date, representing a grant or award rather than a purchase or sale transaction.

The acquisition price for both the restricted stock units and stock options is reported as $0, which is consistent with equity grants awarded as compensation rather than purchased by the executive at fair market value. This represents a common practice wherein executives receive equity awards from their employers as part of their overall compensation package, distinct from open-market purchases or exercises of previously granted options. The filing was executed by Bruce Jacobs, who acted as attorney-in-fact on behalf of Rooney, and was dated July 27, 2026.

Implications for Investors and Shareholder Alignment

The equity compensation awarded to Chief Medical Officer Terence Rooney on July 27, 2026, carries several implications for Kymera Therapeutics shareholders. The substantial size of the grant—114,000 total shares underlying the RSUs and options—signals the company's commitment to retaining senior executive talent in a competitive biopharmaceutical labor market. Given Rooney's responsibility for clinical and medical strategy, the company's investment in his long-term retention through vesting-contingent equity reflects confidence in his continued leadership and the importance of his role in executing the company's development strategy.

From an investor perspective, executive equity grants create alignment between management's financial interests and shareholder value creation. When senior executives hold substantial unvested equity subject to employment conditions, their incentives to remain with the company and drive positive outcomes are strengthened. However, investors may also consider the potential dilution resulting from the issuance of restricted stock units and the exercise of stock options, as these transactions increase the total share count outstanding and thereby affect earnings per share calculations and existing shareholders' ownership percentages.

Biopharmaceutical Industry Context and Executive Compensation Trends

The equity compensation structure granted to Rooney aligns with prevailing practices in the biopharmaceutical industry, where restricted stock units and stock options are standard components of senior executive compensation packages. Biotechnology and drug development companies typically rely heavily on equity-based compensation to attract and retain specialized talent, particularly for roles requiring advanced scientific or medical credentials and significant decision-making authority. The four-year RSU vesting schedule and the multi-tranche option vesting are both consistent with market conventions in this sector.

Kymera Therapeutics, which focuses on targeted protein degradation—a technology platform addressing a wide range of disease areas—operates in a highly competitive segment of the biopharmaceutical industry. Securing and retaining experienced chief medical officers and other senior scientific leaders is essential to advancing the company's pipeline and achieving clinical and regulatory milestones. The equity awards disclosed here represent the company's commitment to compensating its leadership team in a manner competitive with peer organizations and aligned with long-term value creation objectives that benefit all shareholders.

Employment Contingencies and Risk Considerations

The vesting schedules described in the disclosure are expressly contingent upon Terence Rooney's continued employment at Kymera Therapeutics through each respective vesting date. This contingency has significant implications for both the executive and the company. If Rooney's employment terminates before full vesting of the awards, he will forfeit unvested portions of both the restricted stock units and the stock options, unless the company's equity plan or employment agreement provides for accelerated vesting upon certain qualifying events such as death, disability, or change of control.

The filing does not disclose whether acceleration provisions exist in Rooney's award agreements or the company's equity plan, nor does it describe any special termination arrangements or severance provisions. Investors should note that the actual economic value realized by Rooney from these grants depends not only on the company's stock price performance but also on the continuation of his employment and the satisfaction of all vesting conditions. Changes in company leadership, strategic direction, or business circumstances could affect both the likelihood of vesting and the ultimate realization of value from these equity holdings.